Galecto (Galecto) EBIT : $-28.71 Mil (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Galecto EBIT?

Galecto's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was $-5.74 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was $-28.71 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Galecto's annualized ROC % for the quarter that ended in Mar. 2024 was -670.87%. Galecto's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -8,350.55%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Galecto's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 270.56%.

Galecto EBIT Historical Data

The historical data trend for Galecto's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galecto EBIT Chart

Galecto Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-38.97

-33.64

-52.23

-61.21

-36.46

Galecto Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT	Get a 7-Day Free Trial															-13.49	-11.16	-5.86	-5.95	-5.74

Competitive Comparison of Galecto's EBIT

For the Biotechnology subindustry, Galecto's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Galecto's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galecto's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Galecto's EV-to-EBIT falls into.

Galecto EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-28.71 Mil.

Galecto (NAS:GLTO) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Galecto's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	-22.964 * ( 1 - 0% )	/	( (3.162	+	3.684)	/ 2 )
=	-22.964	/	3.423
=	-670.87 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	38.227	-	4.121	-	( 33.151	-	max(0, 5.83	-	36.774	+	33.151	))
=	3.162

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	32.477	-	2.57	-	( 27.171	-	max(0, 4.318	-	30.541	+	27.171	))
=	3.684

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Galecto's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Mar. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-22.964	/	( ( (0.325 + max(-3.742, 0))	+	(0.225 + max(-2.496, 0)) )	/	2 )
=	-22.964	/	( ( 0.325	+	0.225 )	/	2 )
=	-22.964	/	0.275
=	-8,350.55 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	1.905)	-	(4.121	+	0	+	1.526)
=	-3.742

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	1.667)	-	(2.57	+	0	+	1.593)
=	-2.496

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Galecto's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2024 )
	=	-28.706	/	-10.610
	=	270.56 %

Galecto EBIT Related Terms

Thank you for viewing the detailed overview of Galecto's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Galecto (Galecto) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galecto Inc (NAS:GLTO) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ole Maaloes Vej 3, Copenhagen, DNK, DK-2200

Website

https://www.galecto.com

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis-related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.

Executives

Orbimed Advisors Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Bertil Lindmark	officer: Chief Medical Officer	C/O GALECTO, INC., OLE MAALOES VEJ 3, COPENHAGEN N G7 DK-2200
Hans T. Schambye	director, officer: Chief Executive Officer	C/O GALECTO, INC., OLE MAALOES VEJ 3, COPENHAGEN N G7 DK-2200
Stephanie Oestreich	officer: Chief Business Officer	75 STATE STREET, SUITE 100, BOSTON MA 02109
Jonathan Freve	officer: Chief Financial Officer	C/O SPRING BANK PHARMACEUTICALS, INC., 113 CEDAR STREET, STE S-7, MILFORD MA 01757
Garrett Winslow	officer: General Counsel	35 PARKWOOD DRIVE, C/O SPRING BANK PHARMACEUTICALS, INC., HOPKINTON MA 01748
Anne Prener	director	C/O RUBIUS THERAPEUTICS, 399 BINNEY STREET SUITE 300, CAMBRIDGE MA 02139
Dallas Jayson Donald Alexander	director	AIMMUNE THERAPEUTICS, INC., 8000 MARINA BOULEVARD, SUITE 300, BRISBANE CA 94005
Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Chau Quang Khuong	director, 10 percent owner	C/O ORBIMED ADVISORS, 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Stephan Christgau	director	C/O CASTLE & MORGAN HOLDINGS, INC., 425 MARKET STREET, SUITE 2230, SAN FRANCISCO CA 94105
Soren Moller	director	C/O NOVO HOLDINGS A/S, TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Anders Pedersen	officer: Chief Operating Officer	C/O GALECTO, INC., OLE MAALOES VEJ 3, COPENHAGEN N G7 DK-2200
Orbimed Advisors Israel Ii Ltd	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Israel Gp Ii, L.p.	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022